Status:
RECRUITING
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Lead Sponsor:
Bausch & Lomb Incorporated
Conditions:
Glaucoma
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults with Primary Open Angle Glaucoma or Ocular Hypertension
Detailed Description
This study will evaluate the safety and efficacy of BL1107 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. This is a randomized, double-masked, parallel comparison to e...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Ocular hypertension or primary open-angle glaucoma in each eye
- Exclusion criteria:
- History of orthostatic hypotension
- Any active ocular disease
- Anticipated wearing of contact lenses during study
- Contraindication to pupil dilation
Exclusion
Key Trial Info
Start Date :
October 24 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
228 Patients enrolled
Trial Details
Trial ID
NCT07168902
Start Date
October 24 2025
End Date
May 1 2026
Last Update
November 13 2025
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Global Research Management, Inc.
Glendale, California, United States, 91204
2
Eye Research Foundation
Newport Beach, California, United States, 92663
3
Levenson Eye Associates
Jacksonville, Florida, United States, 32204
4
Central Florida Eye Associates
Lakeland, Florida, United States, 33805